A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
Status:
Completed
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Doctors usually treat uveal melanoma with radiotherapy or surgery. But if this cancer
spreads, it is more difficult to treat.
Doctors usually treat uveal melanoma that has spread with a chemotherapy called dacarbazine,
but they are always looking to find new ways to treat uveal melanoma.
This study aims to find out how well Sunitinib works to treat uveal melanoma and to see how
long Sunitinib and Dacarbazine can help to prevent the cancer from getting worse.
Phase:
Phase 2
Details
Lead Sponsor:
The Clatterbridge Cancer Centre NHS Foundation Trust